Sandbox/Alejandro

Jump to navigation Jump to search

Neutropenic Patients Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005[1]

  • Patients with neutropenia require an antimicrobial therapy with a broader coverage.
  • The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
Recommended Duration of Antimicrobial Therapy Based on the Microorganism.
Microorganism Duration of Therapy
 ▸ Gram-negative Bacteria 7-14 days
 ▸ Gram-positive Bacteria 7-10 days
 ▸ Fungi Until clinical resolution

▸ Click on the following categories to expand treatment regimens.

Neutropenia

  ▸  Gram-Negative Bacteria

  ▸  Gram-Positive Bacteria

  ▸  Fungi


Gram-Negative Bacteria
Preferred Regimen
Meropenem 0.5-1 g IV q8h (infuse over 15-30 min or in bolus over 3-5 min)
OR
Imipenem/cilastatin 0.5–1 g IV q6–8h(max: 50mg/kg/day)
OR
Ertapenem 1 g IV/IM q24h
OR
Cefepime 2g IV q8h
OR
Ceftazidime 2g IV q8h
OR
Piperacillin/tazobactam 3.375 g IV q6–8h
Alternative Regimen 1
Amikacin 15 mg/kg/day IV/IM divided q8-12h (max: 15 mg/kg/day)
OR
Gentamicin 3-5 mg/kg/day IV/IM divided q6-8h
OR
Gentamicin 4-7 mg/kg/day IV q24h (adjust dosage based on serum concentrations)
PLUS
Cefepime 2g IV q8h
OR
Piperacillin/tazobactam 3.375 g IV q6–8h (max 24 g/day)
Alternative Regimen 2
Piperacillin/tazobactam 3.375 g IV q6–8h (max 24 g/day)
PLUS
Ciprofloxacin 400mg IV q8h
Gram-Positive Bacteria
Preferred Regimen
Vancomycin† 15-20 mg/kg IV q8-12h
Alternative Regimen
Linezolid 600 mg IV/PO q12h
OR
Daptomycin 4mg/kg IV q24h
† Vancomycin should be discontinued if culture results remain negative after 72-96 hrs
Fungi
Preferred Regimen
Liposomal Amphotericin B 3 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B lipid complex 5 mg/kg/day IV × 1-2 weeks
Alternative Regimen
Voriconazole 6 mg/kg IV q12h x 1 day, then 3 mg/kg IV q12h
OR
Voriconazole 200 mg PO q12h
OR
Caspofungin 70 mg IV once, then 50 mg IV q24h x ≥ 14 days

Cellular Immune Deficient Patients Adapted from Guidelines for Skin and Soft-Tissue Infections CID 2005[1]

  • Patients with cellular immunodeficiency require a pathogen-specific antimicrobial therapy.
  • The duration of antimicrobial therapy should be individualized in accordance with patient's clinical response.
Recommended Duration of Antimicrobial Therapy Based on the Microorganism.
Microorganism Duration of Therapy
 ▸ Nocardia spp 3-12 months
 ▸ Atypical mycobacteria 6-12 months
 ▸ Cryptococcus spp 8-12 weeks
 ▸ Histoplasma spp ≥ 12 months
 ▸ Varicella-zoster virus 7-10 days
 ▸ Herpes simplex virus 7 days
 ▸ Cytomegalovirus 21 days


Bacteria

  ▸  Nocardia spp

  ▸  Atypical mycobacteria

Fungi

  ▸  Cryptococcus spp

  ▸  Histoplasma spp

Viruses

  ▸  Varicella-zoster virus

  ▸  Herpes simplex virus

  ▸  Cytomegalovirus

Nocardia spp
Preferred Regimen
TMP-SMX x 3-12 months
Alternative Regimen 1
Sulfadiazine 2-4 g PO 1 dose
FOLLOWED BY
Sulfadiazine 2-4 g/day PO q4-8h x 3-12 months
Alternative Regimen 1
Imipenem 250-500 mg IV q6-8h x 3-12 months
Atypical mycobacteria†
Preferred Regimen
Clarithromycin 500 mg PO q12h
PLUS
Ethambutol 15 mg/kg PO q24h
WITH OR WITHOUT
Rifabutin 300 mg PO q24h
Alternative Regimen
Azithromycin 500 mg PO q24h
PLUS
Ethambutol 15 mg/kg PO q24h
WITH OR WITHOUT
Rifabutin 300-450 mg PO q24h
† Adapted from Am J Respir Crit Care Med Vol 175. pp 367–416, 2007[2]
Cryptococcus spp
Preferred Regimen
Moderate Severe to Severe Disease
Liposomal Amphotericin B 3 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B deoxycholate 0.7-1 mg/kg/day IV × 1-2 weeks
OR
Amphotericin B lipid complex 5 mg/kg/day IV × 1-2 weeks
FOLLOWED BY
Itraconazole 200 mg PO q12h x ≥12 months
Mild to Moderate Disease
Itraconazole 200 mg PO q12h x ≥12 months
Adapted from Clin Infect Dis. 2007;45(7):807-25.[3]
Histoplasma spp
Preferred Regimen
Liposomal Amphotericin B 3 mg/kg/day x 1- 2 weeks
OR

Amphotericin B lipid complex 5 mg/kg/day x 1- 2 weeks

FOLLOWED BY
Itraconazole 200mg q8h x 3 days
FOLLOWED BY
Itraconazole 200mg q12h x 6-12 months
Varicella-zoster virus
Preferred Regimen
Acyclovir 10-12 mg/kg IV (infusion over 1 hour) q8h x 7-10 days
Alternative Regimen
Famciclovir 500 mg PO x 7-10 days
OR
Valacyclovir 500 mg PO x 7-10 days
Herpes simplex virus
Preferred Regimen
Acyclovir 10 mg/kg IV (infusion over 1 hour) q8h x 7-10 days
Alternative Regimen
Famciclovir 500 mg PO x 7 days
OR
Valacyclovir 500 mg PO x 7 days
Cytomegalovirus
Preferred Regimen
Ganciclovir 5 mg/kg IV q12h x 21 days
Alternative Regimen
Valganciclovir 900 mg PO q12h x 21 days
  1. 1.0 1.1 Dennis L. Stevens, Alan L. Bisno, Henry F. Chambers, E. Dale Everett, Patchen Dellinger, Ellie J. C. Goldstein, Sherwood L. Gorbach, Jan V. Hirschmann, Edward L. Kaplan, Jose G. Montoya & James C. Wade (2005). "Practice guidelines for the diagnosis and management of skin and soft-tissue infections". Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 41 (10): 1373–1406. doi:10.1086/497143. PMID 16231249. Unknown parameter |month= ignored (help)
  2. Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin (2007). "An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X.
  3. Wheat, LJ.; Freifeld, AG.; Kleiman, MB.; Baddley, JW.; McKinsey, DS.; Loyd, JE.; Kauffman, CA. (2007). "Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America". Clin Infect Dis. 45 (7): 807–25. doi:10.1086/521259. PMID 17806045. Unknown parameter |month= ignored (help)